Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) has been assigned an average recommendation of “Buy” from the eleven research firms that are covering the firm, Marketbeat reports. Eleven analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $52.20.
A number of brokerages have issued reports on DNLI. TheStreet lowered shares of Denali Therapeutics from a “c-” rating to a “d+” rating in a research note on Wednesday, September 6th. Wedbush restated an “outperform” rating and set a $31.00 price objective on shares of Denali Therapeutics in a report on Wednesday. B. Riley started coverage on shares of Denali Therapeutics in a report on Wednesday, September 6th. They set a “buy” rating and a $38.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $105.00 target price on shares of Denali Therapeutics in a research note on Thursday, August 31st. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $35.00 target price (down previously from $85.00) on shares of Denali Therapeutics in a research note on Tuesday, October 24th.
Insider Transactions at Denali Therapeutics
Institutional Investors Weigh In On Denali Therapeutics
Large investors have recently bought and sold shares of the company. PNC Financial Services Group Inc. boosted its holdings in Denali Therapeutics by 85.2% during the fourth quarter. PNC Financial Services Group Inc. now owns 1,669 shares of the company’s stock worth $46,000 after purchasing an additional 768 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in Denali Therapeutics by 34.1% during the first quarter. China Universal Asset Management Co. Ltd. now owns 1,851 shares of the company’s stock worth $43,000 after acquiring an additional 471 shares during the period. Assetmark Inc. increased its position in Denali Therapeutics by 49.1% during the third quarter. Assetmark Inc. now owns 2,148 shares of the company’s stock worth $44,000 after acquiring an additional 707 shares during the period. Sandia Investment Management LP bought a new position in Denali Therapeutics during the fourth quarter worth about $70,000. Finally, Point72 Middle East FZE bought a new position in Denali Therapeutics during the fourth quarter worth about $100,000. Institutional investors own 78.04% of the company’s stock.
Denali Therapeutics Trading Down 5.2 %
NASDAQ DNLI opened at $16.22 on Friday. The company has a market cap of $2.24 billion, a PE ratio of -16.72 and a beta of 1.19. Denali Therapeutics has a 1 year low of $15.92 and a 1 year high of $33.31. The stock’s 50-day moving average price is $21.05 and its two-hundred day moving average price is $25.59.
Denali Therapeutics (NASDAQ:DNLI – Get Free Report) last posted its quarterly earnings data on Tuesday, November 7th. The company reported ($0.72) EPS for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.09. Denali Therapeutics had a negative net margin of 36.51% and a negative return on equity of 11.54%. The firm had revenue of $1.30 million during the quarter, compared to analyst estimates of $11.16 million. During the same quarter last year, the business posted ($0.84) EPS. The company’s revenue was down 63.9% on a year-over-year basis. Research analysts forecast that Denali Therapeutics will post -1.16 EPS for the current fiscal year.
Denali Therapeutics Company Profile
Denali Therapeutics Inc, a biopharmaceutical company, developing a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases. It pursues new treatments by assessing genetically validated targets, engineering delivery across the blood-brain barrier, and guiding development through biomarkers that demonstrate target and pathway engagement.
- Five stocks we like better than Denali Therapeutics
- How to Calculate Retirement Income: MarketBeat’s Calculator
- MarketBeat Week in Review – 11/6 – 11/10
- Do ETFs Pay Dividends? What You Need to Know
- Data giants MongoDB and Snowflake just got upgraded
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.